試す 金 - 無料
Jan Vishwas Act 2025: Decriminalisation and penalisation of drug offences through compounding
Express Pharma
|October 2025
Dr Suresh R Saravdekar, Former Assistant Director, Ministry of Medical Education & Research, Maharashtra & Honorary Consultant, Institute of Medical Sciences, Banaras Hindu University, Varanasi informs that with limited resources and overburdened courts, governments are increasingly outsourcing regulation to private or semi-private bodies. In India, this trend is visible in healthcare and pharma, where weak quasi-judicial systems often protect businesses more than the public

Around the world, one thing that is prominent in the current functioning of democracies is that if the government system cannot control and regulate professional businesses due to inadequate manpower and insufficient resources available in the judiciary and regulatory system, the regulatory system is either fully or partially privatised. This is the overall policy of governments seen globally and locally too.
The best example of this can be seen from the constant hike in healthcare charges in private hospital services and other medical expenses. Now it has reached the sky and has become unaffordable for the common people. The Clinical Establishments Act was enacted in 2010 to standardise and regulate private healthcare services in India. But because of high pressure from the private hospital lobby, the Government of India has failed to make the Clinical Establishments Act, 2010 mandatory for private hospitals in all states.
Under such a situation, to fill up this gap, the procedure of 'Accreditation' is adopted in many developed countries. The Joint Commission is one of the most widely used accreditation organisations. The International Society for Quality in Healthcare (ISQua) is the umbrella organisation responsible for accrediting the Joint Commission accreditation scheme in the US and Accreditation Canada International, as well as accreditation organisations in the UK and Australia. These bodies ensure the quality of health services and issue certification based on international standards which are continuously updated to accommodate needless new technological developments. This results in continuously hiking the charges to the patient by subjecting them to over-drugging and over-diagnosis.
このストーリーは、Express Pharma の October 2025 版からのものです。
Magzter GOLD を購読すると、厳選された何千ものプレミアム記事や、10,000 以上の雑誌や新聞にアクセスできます。
すでに購読者ですか? サインイン
Express Pharma からのその他のストーリー

Express Pharma
Flexotherm Heating Tapes & Cords
Typical Applications of Heating Tapes and Cords in Industrial Solvent Handling
1 mins
October 2025

Express Pharma
DRIVING INDIA'S INNOVATION EDGE
Pharma leaders come together to highlight Bengaluru's R&D strength, tech ecosystem, and talent pool to power India Pharma Inc's shift from generics to innovation and global leadership
16 mins
October 2025

Express Pharma
Al compass: Transforming pharma commercialisation
As the world evolves at a rapid pace, pharma companies are embracing smarter approaches, leveraging Al across nearly every aspect of commercialisation, from market forecasting and personalised marketing to dynamic pricing and beyond. In this article, Neha Aathavale takes the pulse of the industry to explore who is taking note and how companies are beginning to put Al into action in their commercial operations
7 mins
October 2025

Express Pharma
PRIME NEO: New age doors from Gandhi Automation
Gandhi Automations presents the multi-composites, high-performance door PRIME NEO for clean environments. Complete Washable, Greater Sealing and Pressure Resistant.
1 mins
October 2025

Express Pharma
Unani Medicine: At crossroads of tradition and modernity
Manufacturers, academic institutions and research councils are working together to elevate Unani medicine through clinical validation and policy alignment with international standards, finds Swati Rana
7 mins
October 2025

Express Pharma
Single-Use Technologies in Biologics Manufacturing: Benefits, Challenges, and Growing Demand
The biopharmaceutical industry is increasingly adopting single-use technology (SUT) to achieve flexibility, cost efficiency, and faster time-to-market. Compared with stainless steel systems, SUT reduces capital investment, eliminates cleaning and sterilization steps, lowers contamination risk, and shortens production timelines.
1 min
October 2025

Express Pharma
Sustainable packaging with Romaco and Liveo Research
Recycable blister packs
3 mins
October 2025

Express Pharma
With India soon to be three times the population of the EU, it makes perfect sense to have manufacturing here
As part of Sweden's Focus Asia programme, a high-level SME delegation recently visited India to strengthen bilateral ties and explore collaborations across sectors including pharma, biotech and others. Building on the momentum of the \"Time for Sweden\" event, the visit underscored Sweden's commitment to innovation, sustainability, and co-creation with India. Among the delegation was Emil Alexander Byström, CEO of SpinChem AB, who in an interaction with Kalyani Sharma shared his insights on how advanced Swedish technologies like biocatalysis and the company's patented Rotating Bed Reactor (RBR) can accelerate India's pharma and biotech innovation journey while supporting sustainable growth.
3 mins
October 2025

Express Pharma
Cell therapy's next chapter: Industry embraces in-vivo innovation
Nikhil C Bhanumathi, Principal Clinical Lead, Thermo Fisher Scientific highlights that cell therapy is entering a bold new phase in 2025 as the industry shifts from complex, lab-based ex vivo CAR-T to faster, more accessible in vivo CAR-T innovations. This approach promises to expand access, lower costs, and potentially tackle solid tumors and autoimmune diseases
4 mins
October 2025

Express Pharma
Research misconduct ...can delay meaningful and reliable discoveries
Dr Gráinne McNamara, Research Integrity/Publication Ethics Manager, S. Karger AG explores how research misconduct, peer review fraud slow down pharma research. Of particular concern to India is the fact that India-based researchers constitute 5 per cent of articles in life sciences retracted between 1976-2023. India-based researchers also have one of the highest rates of retraction relative to the overall publication output. Over an email exchange with Viveka Roychowdhury, she details how publishers are now deploying AI tools, some of which contributed to the problem in the first place, to detect and avert fraudulent research submissions
6 mins
October 2025
Listen
Translate
Change font size